© Copyright Nostre Net
Diabetic Nephropathy Market Overviewand Analysis By Diagnosis, By Treatment, By
Indication, By End User, Forecast Till 2030
Diabetic Nephropathy Market was valued USD
2.48 billion in 2021 and is expected to reach USD 3.43 billion by 2030 at 6.20%
CAGR during the forecast period 2022-2030. This can be attributed to
rising cases of obesity and diabetes. Immense demand for diagnostic and
imaging tests such as kidney biopsy, blood test, urine test, CT scan, and MRI
scans can fuel the market demand. According to the World Health Organization,
patients with chronic diseases touched a high of 35 million globally.
Diabetic nephropathy, known as diabetic
kidney disease (DKD), is a kidney malady frequently found in patients with type
1 and type 2 diabetes. High prevalence of diabetes globally has culminated in
diabetes co-morbidities. It can cause nephropathy which would require dialysis
or a transplant. The global diabetic nephropathy market report by Market
Research Future (MRFR) provides a quantitative and qualitative analysis by
listing out trends, factors, and restraints with ample figures and statistics
to back up the evidence.
Technological advances in diagnostic
imaging and emphasis on early diagnosis for prevention of diseases are other
drivers of the market. The expansion of the healthcare sector and availability
of these tests at reputed hospitals and clinics can lend credibility to the
trend. Rising number of clinical trials conducted to test the success of drugs
for inhibiting the progress of DKD can provide new growth avenues. Angiotensin
converting enzyme inhibitors (ACEi) have been known to have moderate success in
clinical trials with placebo treatment in reducing the risk of death in
patients with diabetes.
Competitive Outlook
Bayer AG, Siemens AG, AbbVie Inc., Eli
Lilly and Company, Mitsubishi Tanabe Pharma Corporation, Reata Pharmaceuticals,
Inc., Pfizer Inc., Abbott, Merck & Co., Inc., General Electric Company,
Novartis AG, Sanofi, and others are some of the noteworthy players in the
global diabetic nephropathy market. Increased investments in research and
development and drug discovery pertaining to chronic kidney disorders are the
main focus of these players.
Segmentation Analysis
The global diabetic
nephropathy market Outlook is segmented by diagnosis, treatment,
indication, and end-user.
By diagnosis, it is segmented into imaging
tests, urine tests, blood tests, renal function testing, and kidney biopsy. By
treatment, it is segmented into kidney dialysis, medications, and transplant.
By indication, it is segmented into diabetes 1 and diabetes 2. By end-user, it
is segmented into research institutes, hospitals & clinics, diagnostic
centers, and others.
Regional Analysis
Europe, the Americas, Asia Pacific (APAC),
and the Middle East & Africa (MEA) are regions covered in the diabetic
nephropathy market report.
The Americas are pegged to lead the global
market till 2023 due to emphasis on diagnostic tests, constant monitoring of
insulin levels, and large prevalence of chronic kidney disease (CKD). According
to the U.S. National Chronic Kidney Disease, nearly 39 million Americans have
CKD as of 2019. Large awareness levels can drive the regional market demand.
This is exemplified with the American Diabetes Association for creating
programs among diabetics for diabetes management.
The European region is deemed to be driven
by kidney diagnosis tests for the geriatric populace combined with demand for
diagnostic services. Germany is touted to be one of the biggest regions due to
investment in new technologies and favorable reimbursement policies. High
awareness of diabetes and its negligence which can cause kidney disorders is
likely to drive the regional diabetic nephropathy market.
On the other hand, the APAC region is the
third biggest globally and will sustain its ranking till the end of the
forecast period. High prevalence of diabetes in Thailand, China, Japan, and
India combined with chances of DKD in the region due to low patient awareness
levels can work favorably for the market. The large geriatric population in
these countries can also count as a viable factor driving the global diabetic
nephropathy market growth.
About US:
Market Research Future (MRFR), enable customers to
unravel the complexity of various industries through Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R),
Continuous-Feed Research (CFR), and Market Research & Consulting Services.
The Wall